Counteracting the enzymatic activity of dipeptidylpeptidase 4 for potential therapeutic advantage, with an emphasis on cord blood transplantation

dc.contributor.authorBroxmeyer, Hal E.
dc.contributor.departmentMicrobiology and Immunology, School of Medicine
dc.date.accessioned2025-04-25T11:11:55Z
dc.date.available2025-04-25T11:11:55Z
dc.date.issued2013
dc.description.abstractDipeptidylpeptidase (DPP) 4, also known as CD26, is an enzyme present on the surface of a number of different cell types. It is also found within cells and as a soluble protein in body fluids. It can specifically truncate proteins at the penultimate N-terminus residue for some amino acids, such as alanine, proline, serine, and perhaps others. DPP4 has been implicated in regulating the in vitro and in vivo functional activities of a number of hematopoietically active molecules, and this information, along with that on inhibition of DPP4, has been studied in efforts to enhance hematopoietic cell transplantation (HCT), hematopoiesis after stress in mouse models, and in the clinical setting of single-unit cord blood (CB) HCT. This article reviews the current status of this compound's effects on regulatory proteins, the field of CB HCT, a potential role for modulating DPP4 activity in enhancing single-unit CB HCT in adults, and future aspects in context of other cellular therapies and the area of regenerative medicine.
dc.eprint.versionFinal published version
dc.identifier.citationBroxmeyer HE. Counteracting the enzymatic activity of dipeptidylpeptidase 4 for potential therapeutic advantage, with an emphasis on cord blood transplantation. Korean J Intern Med. 2013;28(6):639-645. doi:10.3904/kjim.2013.28.6.639
dc.identifier.urihttps://hdl.handle.net/1805/47451
dc.language.isoen_US
dc.publisherKorean Association of Internal Medicine
dc.relation.isversionof10.3904/kjim.2013.28.6.639
dc.relation.journalThe Korean Journal of Internal Medicine
dc.rightsAttribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourcePMC
dc.subjectDipeptidyl peptidase 4
dc.subjectHematopoietic stem cell transplantation
dc.subjectCytokines
dc.subjectTissue therapy
dc.subjectRegenerative medicine
dc.titleCounteracting the enzymatic activity of dipeptidylpeptidase 4 for potential therapeutic advantage, with an emphasis on cord blood transplantation
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Broxmeyer2013Counteracting-CCBYNC.pdf
Size:
163.52 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: